nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—ABCG2—Dactinomycin—ocular cancer	0.24	0.492	CbGbCtD
Imatinib—ABCG2—Carboplatin—ocular cancer	0.161	0.331	CbGbCtD
Imatinib—ABCB1—Dactinomycin—ocular cancer	0.0866	0.177	CbGbCtD
Imatinib—CA6—ear—ocular cancer	0.00803	0.194	CbGeAlD
Imatinib—CA3—ear—ocular cancer	0.00761	0.184	CbGeAlD
Imatinib—Growth retardation—Dactinomycin—ocular cancer	0.00519	0.103	CcSEcCtD
Imatinib—ABCA3—eye—ocular cancer	0.00368	0.0889	CbGeAlD
Imatinib—Cheilitis—Dactinomycin—ocular cancer	0.00277	0.0548	CcSEcCtD
Imatinib—Ascites—Dactinomycin—ocular cancer	0.0026	0.0513	CcSEcCtD
Imatinib—Myelosuppression—Dactinomycin—ocular cancer	0.00251	0.0497	CcSEcCtD
Imatinib—PIP4K2C—retina—ocular cancer	0.00208	0.0502	CbGeAlD
Imatinib—Febrile neutropenia—Dactinomycin—ocular cancer	0.00196	0.0387	CcSEcCtD
Imatinib—Folliculitis—Dactinomycin—ocular cancer	0.00188	0.0371	CcSEcCtD
Imatinib—Hepatotoxicity—Dactinomycin—ocular cancer	0.00153	0.0302	CcSEcCtD
Imatinib—Necrosis—Dactinomycin—ocular cancer	0.0015	0.0297	CcSEcCtD
Imatinib—CA12—eye—ocular cancer	0.00142	0.0343	CbGeAlD
Imatinib—CSF1R—eye—ocular cancer	0.00135	0.0327	CbGeAlD
Imatinib—Hypocalcaemia—Dactinomycin—ocular cancer	0.00129	0.0255	CcSEcCtD
Imatinib—Ulcer—Dactinomycin—ocular cancer	0.00125	0.0246	CcSEcCtD
Imatinib—SLC47A1—eye—ocular cancer	0.00123	0.0298	CbGeAlD
Imatinib—PDGFRB—eye—ocular cancer	0.0012	0.029	CbGeAlD
Imatinib—Infection—Carboplatin—ocular cancer	0.00113	0.0222	CcSEcCtD
Imatinib—KIT—epithelium—ocular cancer	0.00112	0.0271	CbGeAlD
Imatinib—CA1—eye—ocular cancer	0.00112	0.0271	CbGeAlD
Imatinib—Aplastic anaemia—Dactinomycin—ocular cancer	0.00111	0.0219	CcSEcCtD
Imatinib—PDGFRB—epithelium—ocular cancer	0.0011	0.0265	CbGeAlD
Imatinib—PDGFRA—lymphoid tissue—ocular cancer	0.00108	0.0261	CbGeAlD
Imatinib—Oesophagitis—Dactinomycin—ocular cancer	0.00108	0.0213	CcSEcCtD
Imatinib—ABL1—eye—ocular cancer	0.00107	0.0258	CbGeAlD
Imatinib—Mouth ulceration—Dactinomycin—ocular cancer	0.00107	0.0211	CcSEcCtD
Imatinib—ABL1—retina—ocular cancer	0.00106	0.0256	CbGeAlD
Imatinib—Sepsis—Dactinomycin—ocular cancer	0.00102	0.0202	CcSEcCtD
Imatinib—Pain—Carboplatin—ocular cancer	0.000969	0.0192	CcSEcCtD
Imatinib—Hepatic failure—Dactinomycin—ocular cancer	0.000953	0.0188	CcSEcCtD
Imatinib—CSF1R—lymphoid tissue—ocular cancer	0.000952	0.023	CbGeAlD
Imatinib—Body temperature increased—Carboplatin—ocular cancer	0.000896	0.0177	CcSEcCtD
Imatinib—Lethargy—Dactinomycin—ocular cancer	0.000874	0.0173	CcSEcCtD
Imatinib—KIT—lymphoid tissue—ocular cancer	0.000865	0.0209	CbGeAlD
Imatinib—PDGFRB—lymphoid tissue—ocular cancer	0.000845	0.0204	CbGeAlD
Imatinib—CA1—lymphoid tissue—ocular cancer	0.000791	0.0191	CbGeAlD
Imatinib—Aspartate aminotransferase increased—Dactinomycin—ocular cancer	0.000771	0.0152	CcSEcCtD
Imatinib—Toxic epidermal necrolysis—Dactinomycin—ocular cancer	0.000771	0.0152	CcSEcCtD
Imatinib—ABL1—lymphoid tissue—ocular cancer	0.000753	0.0182	CbGeAlD
Imatinib—Dysphagia—Dactinomycin—ocular cancer	0.00074	0.0146	CcSEcCtD
Imatinib—CA2—eye—ocular cancer	0.000728	0.0176	CbGeAlD
Imatinib—CA2—retina—ocular cancer	0.000721	0.0174	CbGeAlD
Imatinib—Pancytopenia—Dactinomycin—ocular cancer	0.000703	0.0139	CcSEcCtD
Imatinib—Neutropenia—Dactinomycin—ocular cancer	0.000692	0.0137	CcSEcCtD
Imatinib—CA2—epithelium—ocular cancer	0.000665	0.0161	CbGeAlD
Imatinib—Pneumonia—Dactinomycin—ocular cancer	0.000664	0.0131	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Dactinomycin—ocular cancer	0.000654	0.0129	CcSEcCtD
Imatinib—Stomatitis—Dactinomycin—ocular cancer	0.000643	0.0127	CcSEcCtD
Imatinib—Agranulocytosis—Dactinomycin—ocular cancer	0.000616	0.0122	CcSEcCtD
Imatinib—Hepatitis—Dactinomycin—ocular cancer	0.000592	0.0117	CcSEcCtD
Imatinib—Pharyngitis—Dactinomycin—ocular cancer	0.000588	0.0116	CcSEcCtD
Imatinib—Erythema multiforme—Dactinomycin—ocular cancer	0.00056	0.0111	CcSEcCtD
Imatinib—Flushing—Dactinomycin—ocular cancer	0.00055	0.0109	CcSEcCtD
Imatinib—Chills—Dactinomycin—ocular cancer	0.000531	0.0105	CcSEcCtD
Imatinib—Alopecia—Dactinomycin—ocular cancer	0.000523	0.0103	CcSEcCtD
Imatinib—Erythema—Dactinomycin—ocular cancer	0.000516	0.0102	CcSEcCtD
Imatinib—PTGS1—epithelium—ocular cancer	0.000514	0.0124	CbGeAlD
Imatinib—CA2—lymphoid tissue—ocular cancer	0.000513	0.0124	CbGeAlD
Imatinib—Ill-defined disorder—Dactinomycin—ocular cancer	0.000478	0.00945	CcSEcCtD
Imatinib—Anaemia—Dactinomycin—ocular cancer	0.000476	0.00942	CcSEcCtD
Imatinib—Malaise—Dactinomycin—ocular cancer	0.000465	0.00919	CcSEcCtD
Imatinib—Leukopenia—Dactinomycin—ocular cancer	0.000461	0.00912	CcSEcCtD
Imatinib—Myalgia—Dactinomycin—ocular cancer	0.000439	0.00867	CcSEcCtD
Imatinib—Discomfort—Dactinomycin—ocular cancer	0.000434	0.00857	CcSEcCtD
Imatinib—Oedema—Dactinomycin—ocular cancer	0.000421	0.00832	CcSEcCtD
Imatinib—Infection—Dactinomycin—ocular cancer	0.000418	0.00826	CcSEcCtD
Imatinib—Thrombocytopenia—Dactinomycin—ocular cancer	0.000412	0.00814	CcSEcCtD
Imatinib—Anorexia—Dactinomycin—ocular cancer	0.000401	0.00793	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Dactinomycin—ocular cancer	0.000383	0.00758	CcSEcCtD
Imatinib—Decreased appetite—Dactinomycin—ocular cancer	0.000366	0.00723	CcSEcCtD
Imatinib—Fatigue—Dactinomycin—ocular cancer	0.000363	0.00717	CcSEcCtD
Imatinib—Pain—Dactinomycin—ocular cancer	0.00036	0.00711	CcSEcCtD
Imatinib—Feeling abnormal—Dactinomycin—ocular cancer	0.000347	0.00685	CcSEcCtD
Imatinib—Gastrointestinal pain—Dactinomycin—ocular cancer	0.000344	0.0068	CcSEcCtD
Imatinib—Abdominal pain—Dactinomycin—ocular cancer	0.000333	0.00657	CcSEcCtD
Imatinib—Body temperature increased—Dactinomycin—ocular cancer	0.000333	0.00657	CcSEcCtD
Imatinib—ABCB1—retina—ocular cancer	0.000329	0.00796	CbGeAlD
Imatinib—Hypersensitivity—Dactinomycin—ocular cancer	0.00031	0.00613	CcSEcCtD
Imatinib—ABCB1—epithelium—ocular cancer	0.000304	0.00735	CbGeAlD
Imatinib—Asthenia—Dactinomycin—ocular cancer	0.000302	0.00597	CcSEcCtD
Imatinib—Diarrhoea—Dactinomycin—ocular cancer	0.000288	0.00569	CcSEcCtD
Imatinib—Vomiting—Dactinomycin—ocular cancer	0.000268	0.00529	CcSEcCtD
Imatinib—Rash—Dactinomycin—ocular cancer	0.000265	0.00524	CcSEcCtD
Imatinib—Nausea—Dactinomycin—ocular cancer	0.00025	0.00494	CcSEcCtD
Imatinib—ABCB1—lymphoid tissue—ocular cancer	0.000234	0.00566	CbGeAlD
Imatinib—SLC22A2—Metabolism—GNA11—ocular cancer	6.23e-05	0.000149	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MAML2—ocular cancer	6.23e-05	0.000148	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—CDKN1A—ocular cancer	6.16e-05	0.000147	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—ocular cancer	6.12e-05	0.000146	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—CDKN1A—ocular cancer	6.07e-05	0.000145	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—GNA11—ocular cancer	6.05e-05	0.000144	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—MDM2—ocular cancer	6.02e-05	0.000143	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—EP300—ocular cancer	6.01e-05	0.000143	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CDKN2B—ocular cancer	5.97e-05	0.000142	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—HRAS—ocular cancer	5.89e-05	0.00014	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—EP300—ocular cancer	5.86e-05	0.00014	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—GNAQ—ocular cancer	5.86e-05	0.00014	CbGpPWpGaD
Imatinib—LCK—Disease—CDKN2B—ocular cancer	5.83e-05	0.000139	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—GNA11—ocular cancer	5.81e-05	0.000138	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—GNAQ—ocular cancer	5.8e-05	0.000138	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—GNAQ—ocular cancer	5.79e-05	0.000138	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—HRAS—ocular cancer	5.79e-05	0.000138	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—MDM2—ocular cancer	5.78e-05	0.000138	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—TGFB1—ocular cancer	5.76e-05	0.000137	CbGpPWpGaD
Imatinib—ALB—Hemostasis—CDK2—ocular cancer	5.7e-05	0.000136	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—HDAC1—ocular cancer	5.68e-05	0.000135	CbGpPWpGaD
Imatinib—SLC22A2—Neuronal System—HRAS—ocular cancer	5.66e-05	0.000135	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—TGFB1—ocular cancer	5.66e-05	0.000135	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CDKN2B—ocular cancer	5.65e-05	0.000135	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—GNAQ—ocular cancer	5.63e-05	0.000134	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—CDKN1B—ocular cancer	5.49e-05	0.000131	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—E2F1—ocular cancer	5.48e-05	0.00013	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—GNA11—ocular cancer	5.44e-05	0.00013	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—GNAQ—ocular cancer	5.4e-05	0.000129	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—TGFB1—ocular cancer	5.4e-05	0.000129	CbGpPWpGaD
Imatinib—LCK—Hemostasis—EP300—ocular cancer	5.36e-05	0.000128	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ocular cancer	5.33e-05	0.000127	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—ocular cancer	5.32e-05	0.000127	CbGpPWpGaD
Imatinib—SLC22A1—Neuronal System—HRAS—ocular cancer	5.27e-05	0.000126	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CDKN1B—ocular cancer	5.27e-05	0.000126	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—E2F1—ocular cancer	5.18e-05	0.000124	CbGpPWpGaD
Imatinib—KIT—Immune System—MDM2—ocular cancer	5.12e-05	0.000122	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—AKT1—ocular cancer	5.11e-05	0.000122	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CDKN2B—ocular cancer	5.09e-05	0.000121	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—CDKN1A—ocular cancer	5.07e-05	0.000121	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—GNAQ—ocular cancer	5.05e-05	0.00012	CbGpPWpGaD
Imatinib—CA2—Metabolism—EP300—ocular cancer	4.94e-05	0.000118	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CDKN1A—ocular cancer	4.87e-05	0.000116	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—MDM2—ocular cancer	4.85e-05	0.000115	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—HRAS—ocular cancer	4.82e-05	0.000115	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—EP300—ocular cancer	4.82e-05	0.000115	CbGpPWpGaD
Imatinib—CA1—Metabolism—EP300—ocular cancer	4.74e-05	0.000113	CbGpPWpGaD
Imatinib—KIT—Disease—MDM2—ocular cancer	4.73e-05	0.000113	CbGpPWpGaD
Imatinib—KIT—Immune System—CDKN1B—ocular cancer	4.67e-05	0.000111	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—E2F1—ocular cancer	4.67e-05	0.000111	CbGpPWpGaD
Imatinib—LCK—Hemostasis—TGFB1—ocular cancer	4.66e-05	0.000111	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—TP53—ocular cancer	4.66e-05	0.000111	CbGpPWpGaD
Imatinib—CA14—Metabolism—AKT1—ocular cancer	4.63e-05	0.00011	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—HRAS—ocular cancer	4.63e-05	0.00011	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—HRAS—ocular cancer	4.57e-05	0.000109	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HDAC1—ocular cancer	4.56e-05	0.000109	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—EP300—ocular cancer	4.54e-05	0.000108	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—HRAS—ocular cancer	4.54e-05	0.000108	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MDM2—ocular cancer	4.52e-05	0.000108	CbGpPWpGaD
Imatinib—CA6—Metabolism—AKT1—ocular cancer	4.51e-05	0.000108	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GNA11—ocular cancer	4.51e-05	0.000108	CbGpPWpGaD
Imatinib—PDGFRA—Disease—MDM2—ocular cancer	4.47e-05	0.000107	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—HRAS—ocular cancer	4.45e-05	0.000106	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CDKN1B—ocular cancer	4.42e-05	0.000105	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—HRAS—ocular cancer	4.38e-05	0.000104	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ocular cancer	4.38e-05	0.000104	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—MDM2—ocular cancer	4.37e-05	0.000104	CbGpPWpGaD
Imatinib—KIT—Disease—CDKN1B—ocular cancer	4.32e-05	0.000103	CbGpPWpGaD
Imatinib—KIT—Immune System—CDKN1A—ocular cancer	4.31e-05	0.000103	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—AKT1—ocular cancer	4.26e-05	0.000101	CbGpPWpGaD
Imatinib—ABL1—Immune System—MDM2—ocular cancer	4.25e-05	0.000101	CbGpPWpGaD
Imatinib—CA7—Metabolism—AKT1—ocular cancer	4.21e-05	0.0001	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GNAQ—ocular cancer	4.2e-05	0.0001	CbGpPWpGaD
Imatinib—CA9—Metabolism—EP300—ocular cancer	4.16e-05	9.92e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CDKN1B—ocular cancer	4.12e-05	9.83e-05	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—HRAS—ocular cancer	4.11e-05	9.8e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—EP300—ocular cancer	4.1e-05	9.78e-05	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—AKT1—ocular cancer	4.09e-05	9.74e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—CDKN1B—ocular cancer	4.09e-05	9.73e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CDKN2B—ocular cancer	4.08e-05	9.73e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CDKN1A—ocular cancer	4.08e-05	9.73e-05	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—AKT1—ocular cancer	4.03e-05	9.6e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MDM2—ocular cancer	4.03e-05	9.6e-05	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—HRAS—ocular cancer	4.01e-05	9.55e-05	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—AKT1—ocular cancer	4.01e-05	9.55e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CDKN1B—ocular cancer	3.99e-05	9.5e-05	CbGpPWpGaD
Imatinib—KIT—Disease—CDKN1A—ocular cancer	3.98e-05	9.49e-05	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—HRAS—ocular cancer	3.95e-05	9.41e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CCND1—ocular cancer	3.93e-05	9.37e-05	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—AKT1—ocular cancer	3.93e-05	9.37e-05	CbGpPWpGaD
Imatinib—CA12—Metabolism—AKT1—ocular cancer	3.9e-05	9.3e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GNA11—ocular cancer	3.89e-05	9.26e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—EP300—ocular cancer	3.89e-05	9.26e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—CDKN1B—ocular cancer	3.88e-05	9.26e-05	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—AKT1—ocular cancer	3.87e-05	9.22e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—TP53—ocular cancer	3.83e-05	9.13e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CDKN1A—ocular cancer	3.81e-05	9.07e-05	CbGpPWpGaD
Imatinib—KIT—Disease—EP300—ocular cancer	3.79e-05	9.03e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—CDKN1A—ocular cancer	3.77e-05	8.98e-05	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—AKT1—ocular cancer	3.75e-05	8.94e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—E2F1—ocular cancer	3.75e-05	8.93e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ocular cancer	3.7e-05	8.81e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—CDKN1B—ocular cancer	3.68e-05	8.77e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CDKN1A—ocular cancer	3.68e-05	8.76e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—HRAS—ocular cancer	3.67e-05	8.74e-05	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—AKT1—ocular cancer	3.63e-05	8.65e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—EP300—ocular cancer	3.62e-05	8.63e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GNAQ—ocular cancer	3.61e-05	8.61e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—EP300—ocular cancer	3.59e-05	8.55e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—CDKN1A—ocular cancer	3.58e-05	8.54e-05	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—AKT1—ocular cancer	3.54e-05	8.43e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—MDM2—ocular cancer	3.5e-05	8.35e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—EP300—ocular cancer	3.5e-05	8.34e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GNA11—ocular cancer	3.49e-05	8.31e-05	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—AKT1—ocular cancer	3.49e-05	8.31e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—EP300—ocular cancer	3.41e-05	8.13e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GNA11—ocular cancer	3.41e-05	8.11e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—CDKN1A—ocular cancer	3.4e-05	8.09e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MDM2—ocular cancer	3.31e-05	7.89e-05	CbGpPWpGaD
Imatinib—KIT—Disease—MYC—ocular cancer	3.3e-05	7.87e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—HRAS—ocular cancer	3.3e-05	7.86e-05	CbGpPWpGaD
Imatinib—KIT—Disease—TGFB1—ocular cancer	3.29e-05	7.85e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GNAQ—ocular cancer	3.24e-05	7.73e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—AKT1—ocular cancer	3.24e-05	7.71e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MDM2—ocular cancer	3.23e-05	7.71e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—EP300—ocular cancer	3.23e-05	7.7e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GNA11—ocular cancer	3.21e-05	7.64e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—EP300—ocular cancer	3.2e-05	7.63e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—CDKN1B—ocular cancer	3.2e-05	7.62e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GNA11—ocular cancer	3.18e-05	7.58e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—HRAS—ocular cancer	3.17e-05	7.55e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GNAQ—ocular cancer	3.17e-05	7.54e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MYC—ocular cancer	3.16e-05	7.52e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TGFB1—ocular cancer	3.15e-05	7.5e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MDM2—ocular cancer	3.13e-05	7.46e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—MYC—ocular cancer	3.13e-05	7.45e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—TGFB1—ocular cancer	3.12e-05	7.43e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CDKN1B—ocular cancer	3.02e-05	7.2e-05	CbGpPWpGaD
Imatinib—CA2—Metabolism—AKT1—ocular cancer	2.99e-05	7.11e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GNAQ—ocular cancer	2.98e-05	7.11e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GNAQ—ocular cancer	2.96e-05	7.05e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CDKN1B—ocular cancer	2.95e-05	7.04e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—CDKN1A—ocular cancer	2.95e-05	7.03e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—EP300—ocular cancer	2.92e-05	6.95e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—AKT1—ocular cancer	2.91e-05	6.94e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CCND1—ocular cancer	2.88e-05	6.87e-05	CbGpPWpGaD
Imatinib—CA1—Metabolism—AKT1—ocular cancer	2.86e-05	6.82e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CDKN1B—ocular cancer	2.86e-05	6.82e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MDM2—ocular cancer	2.82e-05	6.73e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MYC—ocular cancer	2.82e-05	6.71e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—TGFB1—ocular cancer	2.81e-05	6.69e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—HRAS—ocular cancer	2.81e-05	6.69e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—EP300—ocular cancer	2.81e-05	6.69e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—AKT1—ocular cancer	2.8e-05	6.67e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CDKN1A—ocular cancer	2.79e-05	6.64e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TGFB1—ocular cancer	2.78e-05	6.63e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CCND1—ocular cancer	2.73e-05	6.5e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CDKN1A—ocular cancer	2.73e-05	6.49e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GNA11—ocular cancer	2.72e-05	6.48e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HRAS—ocular cancer	2.66e-05	6.34e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EP300—ocular cancer	2.65e-05	6.32e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CDKN1A—ocular cancer	2.64e-05	6.29e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—ocular cancer	2.62e-05	6.24e-05	CbGpPWpGaD
Imatinib—KIT—Disease—HRAS—ocular cancer	2.59e-05	6.18e-05	CbGpPWpGaD
Imatinib—LCK—Disease—EP300—ocular cancer	2.59e-05	6.18e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—ocular cancer	2.59e-05	6.18e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CDKN1B—ocular cancer	2.58e-05	6.14e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GNAQ—ocular cancer	2.53e-05	6.02e-05	CbGpPWpGaD
Imatinib—CA9—Metabolism—AKT1—ocular cancer	2.52e-05	5.99e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EP300—ocular cancer	2.51e-05	5.99e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—AKT1—ocular cancer	2.48e-05	5.91e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—HRAS—ocular cancer	2.48e-05	5.91e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCND1—ocular cancer	2.46e-05	5.86e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—HRAS—ocular cancer	2.46e-05	5.85e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HRAS—ocular cancer	2.4e-05	5.71e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—ocular cancer	2.39e-05	5.69e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CDKN1A—ocular cancer	2.38e-05	5.67e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—AKT1—ocular cancer	2.35e-05	5.59e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—HRAS—ocular cancer	2.33e-05	5.56e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MYC—ocular cancer	2.31e-05	5.51e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TGFB1—ocular cancer	2.31e-05	5.5e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—ocular cancer	2.29e-05	5.46e-05	CbGpPWpGaD
Imatinib—KIT—Disease—AKT1—ocular cancer	2.29e-05	5.46e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MDM2—ocular cancer	2.27e-05	5.4e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EP300—ocular cancer	2.26e-05	5.39e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MYC—ocular cancer	2.26e-05	5.38e-05	CbGpPWpGaD
Imatinib—LCK—Disease—TGFB1—ocular cancer	2.25e-05	5.37e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HRAS—ocular cancer	2.21e-05	5.27e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—HRAS—ocular cancer	2.19e-05	5.22e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MYC—ocular cancer	2.19e-05	5.22e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—AKT1—ocular cancer	2.19e-05	5.21e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TGFB1—ocular cancer	2.18e-05	5.2e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—AKT1—ocular cancer	2.17e-05	5.16e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—AKT1—ocular cancer	2.12e-05	5.04e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—EP300—ocular cancer	2.1e-05	5.01e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GNA11—ocular cancer	2.1e-05	5e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—EP300—ocular cancer	2.09e-05	4.97e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—EP300—ocular cancer	2.08e-05	4.96e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CDKN1B—ocular cancer	2.07e-05	4.93e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—AKT1—ocular cancer	2.06e-05	4.91e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—ocular cancer	2.04e-05	4.86e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—EP300—ocular cancer	2.02e-05	4.82e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCND1—ocular cancer	1.97e-05	4.7e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MYC—ocular cancer	1.97e-05	4.7e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TGFB1—ocular cancer	1.97e-05	4.69e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—AKT1—ocular cancer	1.95e-05	4.65e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GNAQ—ocular cancer	1.95e-05	4.65e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—EP300—ocular cancer	1.94e-05	4.62e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—AKT1—ocular cancer	1.94e-05	4.61e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—HRAS—ocular cancer	1.92e-05	4.58e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CDKN1A—ocular cancer	1.91e-05	4.55e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—ocular cancer	1.9e-05	4.52e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—HRAS—ocular cancer	1.82e-05	4.33e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EP300—ocular cancer	1.82e-05	4.33e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—ocular cancer	1.8e-05	4.28e-05	CbGpPWpGaD
Imatinib—LCK—Disease—HRAS—ocular cancer	1.77e-05	4.23e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—HRAS—ocular cancer	1.72e-05	4.1e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—AKT1—ocular cancer	1.7e-05	4.04e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—ocular cancer	1.62e-05	3.86e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AKT1—ocular cancer	1.6e-05	3.82e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MYC—ocular cancer	1.58e-05	3.77e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TGFB1—ocular cancer	1.58e-05	3.76e-05	CbGpPWpGaD
Imatinib—LCK—Disease—AKT1—ocular cancer	1.57e-05	3.73e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—HRAS—ocular cancer	1.55e-05	3.69e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AKT1—ocular cancer	1.52e-05	3.62e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—EP300—ocular cancer	1.51e-05	3.59e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AKT1—ocular cancer	1.37e-05	3.26e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—ocular cancer	1.3e-05	3.1e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—EP300—ocular cancer	1.3e-05	3.09e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—AKT1—ocular cancer	1.27e-05	3.03e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—AKT1—ocular cancer	1.26e-05	3e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—AKT1—ocular cancer	1.26e-05	3e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HRAS—ocular cancer	1.24e-05	2.96e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—AKT1—ocular cancer	1.22e-05	2.91e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—AKT1—ocular cancer	1.17e-05	2.79e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—EP300—ocular cancer	1.17e-05	2.78e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—EP300—ocular cancer	1.14e-05	2.71e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AKT1—ocular cancer	1.1e-05	2.61e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—EP300—ocular cancer	1.07e-05	2.55e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—EP300—ocular cancer	1.06e-05	2.53e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—AKT1—ocular cancer	9.11e-06	2.17e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—EP300—ocular cancer	9.08e-06	2.16e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—AKT1—ocular cancer	7.85e-06	1.87e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AKT1—ocular cancer	7.04e-06	1.68e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—EP300—ocular cancer	7.01e-06	1.67e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AKT1—ocular cancer	6.87e-06	1.64e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AKT1—ocular cancer	6.48e-06	1.54e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AKT1—ocular cancer	6.42e-06	1.53e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AKT1—ocular cancer	5.49e-06	1.31e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKT1—ocular cancer	4.24e-06	1.01e-05	CbGpPWpGaD
